Hologic, Inc. $HOLX Stock Holdings Lowered by Royal Bank of Canada

Royal Bank of Canada reduced its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 17.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 365,284 shares of the medical equipment provider's stock after selling 77,485 shares during the quarter. Royal Bank of Canada owned 0.16% of Hologic worth $22,564,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Alamea Verwaltungs GmbH bought a new stake in shares of Hologic in the 1st quarter worth approximately $702,000. Retirement Planning Co of New England Inc. bought a new stake in shares of Hologic in the 1st quarter worth approximately $278,000. Quarry LP raised its holdings in shares of Hologic by 89.9% in the 1st quarter. Quarry LP now owns 3,713 shares of the medical equipment provider's stock worth $229,000 after purchasing an additional 1,758 shares in the last quarter. Vident Advisory LLC increased its position in shares of Hologic by 256.6% in the first quarter. Vident Advisory LLC now owns 20,933 shares of the medical equipment provider's stock worth $1,293,000 after acquiring an additional 15,063 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Hologic by 17.1% in the first quarter. The Manufacturers Life Insurance Company now owns 2,795,137 shares of the medical equipment provider's stock worth $172,656,000 after acquiring an additional 408,535 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on HOLX. Wall Street Zen raised shares of Hologic from a "hold" rating to a "buy" rating in a research report on Sunday. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. Morgan Stanley lifted their target price on shares of Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Stephens dropped their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Stock Down 0.3%

Hologic stock opened at $66.54 on Tuesday. The firm has a market cap of $14.80 billion, a PE ratio of 27.61, a P/E/G ratio of 2.42 and a beta of 0.57. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The firm's 50 day moving average price is $66.37 and its two-hundred day moving average price is $62.60. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company's revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.